TISSIUM Receives CE Mark for ECLIPSIUM Hernia System
The light-activated medical device is cleared for non-penetrating mesh fixation in Europe.
Updated on Oct. 21, 2026 in Healthcare
Live Poll
Would you prefer new surgical technologies that prioritize patient comfort over traditional, invasive fixation methods?
Medical technology firm TISSIUM has secured a CE mark for its ECLIPSIUM system, allowing for the commercialization of its hernia repair solution across Europe. The device is designed for the non-penetrating fixation of surgical meshes used in ventral hernia repair.
Why it matters
ECLIPSIUM offers an alternative to traditional hernia fixation methods like sutures and tacks, which are frequently linked to postoperative pain and tissue trauma. By utilizing a light-activated polymer, the system aims to improve patient outcomes through atraumatic fixation.
The ECLIPSIUM system is engineered to handle surgical mesh implants ranging between 15 and 20 centimeters in size. The device regulatory path relied on clinical data gathered from the ALPHA study conducted in Belgium and Spain.
The players
TISSIUM
Headquartered in France, this company specializes in the development of innovative medical devices and bioabsorbable polymers.
The details
The system utilizes light-activated polymers to secure mesh to soft tissue, effectively replacing standard penetrating methods. This technology provides surgeons with increased control over the precise positioning of the mesh during complex procedures.
Timeline
TISSIUM was founded in 2013.
The FDA granted marketing authorization for COAPTIUM CONNECT in 2025.
ECLIPSIUM received its CE mark on October 21, 2026.
The European commercial release for the system is slated for 2027.
Market Landscape
The transition toward non-penetrating fixation tools marks a significant shift away from legacy mechanical fasteners like tacks. This development positions TISSIUM to capture market share from traditional manufacturers by offering a specialized, minimally invasive alternative.
Patients undergoing ventral hernia repair may benefit from reduced postoperative pain and lower tissue trauma compared to traditional procedures. Surgeons will gain access to a new, light-activated method for precise mesh placement upon the system's scheduled commercial release.
The takeaway
Advancements in light-activated polymers reflect a broader industry trend toward reducing surgical trauma through biological material innovation. Clinicians can monitor the ongoing UNITE clinical trial for further data on the performance of the system in U.S. patient populations.
What happens next
TISSIUM is expected to begin the commercial introduction of the ECLIPSIUM system in European markets in 2027.
Further reading
Learn more about the latest innovations in medical devices in our Healthcare section.
Live Poll
Would you prefer new surgical technologies that prioritize patient comfort over traditional, invasive fixation methods?
